Topics

Novel therapy – bimekizumab – potential psoriatic arthritis treatment

01:00 EST 14 Feb 2020 | Arthritis Digest

Bimekizumab is a monoclonal antibody that selectively neutralises interleukin 17A and interleukin 17F, so is being tested for people with psoriatic arthritis. The latest findings, reported in the Lancet, are encouraging. A total of 206 people with psoriatic arthritis were split into groups: 42 people were in a placebo group and the others received varying […]

The post Novel therapy – bimekizumab – potential psoriatic arthritis treatment appeared first on Arthritis Digest.

Original Article: Novel therapy – bimekizumab – potential psoriatic arthritis treatment

NEXT ARTICLE

More From BioPortfolio on "Novel therapy – bimekizumab – potential psoriatic arthritis treatment"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....